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5I. INTRODUCTION
At its Helsinki meeting in December 1999, the Council of the European Union
formally adopted the European Union drugs strategy (2000–04). The strategy has
been translated into concrete action in the third EU action plan on drugs. The action
plan recommends that the Commission and Member States join efforts to reduce
crime linked to drugs, notably juvenile and urban delinquency. Within this context, the
EMCDDA contributes proactively to informing policy-makers and the public about
drug users and drug addicts in the criminal justice system, including after arrest,
alternatives to prison and treatment facilities within the penal system in EU Member
States.
In line with EU priorities, the EMCDDA launched the study ‘Assistance to drug users
in European Union prisons’ in December 1999. The aim of the study – commissioned
from Dr Heino Stöver from the University of Oldenburg – was to provide an overview
of the situation and the demand and harm reduction responses in a setting
characterised as being enormously relevant to Member States’ efforts to reduce
crime linked to drugs. This abridged version highlights the main findings of the
extensive research that was undertaken during the course of this project. The full
report will be published by ENDHASP (European Network on Drugs and HIV/AIDS
Services in Prison) in collaboration with the EMCDDA and will be available by the
end of 2001.
Margareta Nilson
Programme coordinator – Drug-related responses
6II. DESCRIPTION OF THE SITUATION
KEY FACTS
Drugs are seen as one of the main problems of the current prison system in Europe
and in other countries in the world. The high costs of incarceration are of great
concern.
In most European prisons the spread of drug use has become a real problem. Some
experts say that prisons provide environments that sustain substance abuse among
users and even foster drug use in non users and some empirical evidence exists to
support this. Drugs are widespread, used as addictive substances or to cope with
lack of work, stress and boredom behind bars. Psychoactive substances seem to be
easily available in many prisons, although the frequency of use differs from drug use
in the community. Many prisoners report that drugs are the central currency in prison.
In some countries there is a widespread use of psychoactive medication – in
particular by women – prescribed by prison doctors.
It is difficult to draw a detailed picture of prison drug use in one country and even
more so for the 15 Member States. Drug use in prison takes place in extreme
secrecy. According to estimates by the UN and WHO and information provided by
EMCDDA Reitox focal points, drug users are proportionally over represented among
the 350 000 people imprisoned throughout Europe. Figures of lifetime prevalence of
any illicit drug given by European prisons differ widely, from 15 to 90%.  Considering
the high number of prison entrances and releases (turnover rate), 180 000–600 000
drug users pass through the system annually.
Drug-using patterns by young offenders show less cautious attitudes to drug use and
include higher risks in injecting drug use. This may be due to feelings of inviolability.
II.1. Definitions
The variety of definitions for the term ‘drug user’ in the prisons and prison
administration in different Member States (see Table 1) needs to be taken into
account when interpreting the estimated number of drug users (shown in Table 2).
Although all EU countries report that drug users are a significant and extremely
problematic part of the total prison population, only a few countries provided clear
definitions of the term. It has recently been pointed out that none of the reporting
countries in their Council of Europe survey "has a comprehensive system to quantify
the scale of this problem, even though in most countries it is assumed that this group
makes up a significant part of criminal justice and prison populations"
(Turnbull/McSweeney, 2000).
7Often the definition focuses very generally on the length of drug use and the type of
drug being used. Broad or even non-existent definitions make it extremely difficult to
compare the situations of drug-using prisoners in different countries.
Table 1: Examples of definition of drug users in prison
Country Definition Source
Belgium “Any user of sleeping pills, narcotics and other
psychotropic substances that can create dependence
and for which the user has no medical prescription”
Ministry of Justice
Denmark “Drug addicts are defined as persons who more than
just a few times have taken one or more euphoriants
within the last six months before incarceration”
Ministry of Justice, 3
July 2000
France “Regular use of drugs or of psychoactive medication,
diverted from its proper use, during the year preceding
the date of imprisonment.”
Charlotte Trabut
French Report to
Pompidou Group,
2000
Germany “Drug addicted is used as a synonym for a user of one
or more drugs with a physical or psychological
dependency potential”
State of North Rhine
Westfalia, Germany
Portugal “Drug use by drug in use (both legal and illegal drugs
included)”
Machado Rodrigues,
L. 2000
Spain “Suffer from problems related to the consumption of
psychoactive substances”
Garzon,
Otamendi/Silvosa
20000
Sweden “The notion of drug misuse covers all forms of drug use
without a medical prescription. Anyone known to have
misused drugs during the twelve months prior to
deprivation of liberty is classified as a drug misuser”
Ekström et al. 1999
II.2. Characteristics of drug use in prisons
The number of prisoners in the 15 Member States of the European Union is
estimated to be 350 000 – a ratio of 94 per 100 000 inhabitants – as compared with
645 in the USA.
The highest prison population per 100 000 inhabitants (see Table 2) is found in
Portugal, Spain, England/Wales and Scotland, followed by Germany, France and
Italy. However, the rate per inhabitant is lower in the Scandinavian countries
(Finland, Denmark, Sweden) and in Ireland. The average percentage of females in
the prison population is between 2.5 and 6%. There are three exceptions – Spain
(9.2%) and Portugal (9.7%), where the female prison population is comparatively
high and Denmark where the female prison population (0.5%) is the lowest. The
Netherlands, Italy and France have the highest proportions of remand prisoners
among their total prison population (60.1, 45.5 and 38.7% respectively).
In Table 2 it is important to note that the figures represent inmates on any one day
and not the total population during a year. This figure has to be multiplied with the
‘turnover rate’ (all prisoners being in prison over one year in relation to the cross-
sectional data above) which is about an average of 3 in the EU countries.
8The figures differ widely not only because of the different levels of drug use in prison
but also due to the different definitions applied. The prevalence of drug use varies to
a very great extent. Drug use is more widespread in:
· female than in male prisons;1
· city prisons than in prisons in the countryside;
· juvenile than adult prisons;
· prisons with high percentage of drug user/dealer near a border.
Table 2: Prisons, prisoners and ratio per 100 000
Country Total
number of
prisons3
Total number of
prisoners
(including remand
prisoners)
Number of female
prisoners (%)
Ratio per 100 000
inhabitants
Date
Austria 29 6 973 406 (5.8%) 84 10/2000
Belgium 33 7 867 331 (4.4%) 78 31.12.98
Denmark 14 3 477 177 (0.5%) 65 Average 1999
Finland 22 2 663 132 (5%) 56 31.12.99
France 185 52 122 1 938 (3.7%) 90 1.7.2000
Germany 222 76 495 3 473 (4.5%) 94 31.3.2000
Greece 28 1 7 280 1 436 (6%) 51 7 *
Ireland 18 1 2 983 1 80 (2.7 %) 7 79 *
Italy 220 51 604 4 2 580 (5%) 90 *
Luxembourg 2 380 22 (5.8%) 89,83 *
Netherlands 39 1 12 553 1 564 (4.5%) 75 *
Portugal 53 12 937 1 410 (9.7%) 147 15.12.1999
Spain 38 365 5 ,6 3 523 (9.2%) 96.6 1.1.1999
Sweden 55 5 484 3 12 (5.7%) 61.8 1.10.2000
England/
Wales
132 1 65 298 1 2 299 (4.1%) 7 106.8 7 *
Scotland 15 6 029 212 (3.5%) 118.0 1999
1 according to Muscat 2000; 2 Koulierakis et al. 1999; 3 including all custodial establishments; 4 DAP – Justice
Department; 5 not including Catalonia sovereign in this field, 6 according to statistics on the prison population from
the Directorate General of  Penitentiary Institutions; 7 1st September 1996 (Council of Europe) 8
* = not available.
It is difficult to draw a detailed picture of prison drug use in one country and even
more so for the 15 Member States. Drug use in prison takes place in extreme
                                                
1 Except Belgium where more woman are incarcerated for drug offences, but less drug use in female
prison sections occurs .
9secrecy and isolated factors such as figures of seizure quantities, discovery of
needles/syringes or positive urine testing rates taken on their own only reflect only a
part of the situation. Patterns of drug use vary considerably between different groups
in the prison population. For instance, drug use among female prisoners is
significantly distinct from men, with different levels and types of misuse and different
motivations and behavioural consequences. Only by collecting and collating several
types of data can an impression of drug use in prison be gained. A typical profile for
the group of drug users finally ending up in prison would include the following
characteristics: very socially deprived, often poly-drug users, with several stays in
prison, several treatment attempts, high incidence of relapse, with severe health
damage (including irreversible infectious diseases).
There are different factors which might indicate the extent of drug use in prison. On
the one hand there are scientifically acquired data such as prevalence studies, which
often reflect the situation in no more than one prison. Due to the heterogeneous
nature of the population from one prison to another in one region and in one country,
these isolated cross-sectional studies cannot be taken as representative of the
situation as a whole – juvenile and women's prisons, and prisons with many migrants
may have totally different drug use prevalence figures.
The number of drug-law offences in most EU countries has consistently risen over
the past 15 years. Accordingly the number of drug users in prisons has risen:
ENDHASP (European Network of Drug and HIV/AIDS Services in Prison) estimated
that 46.5% would be users of illegal drugs prior to imprisonment. The EMCDDA
Annual Report (1999) signals that between 15 and 50% of prisoners in the European
Union have or have had problems with illicit drug use.
Table 3: Proportion of drug users among prisoners
Country Proportion of drug users
among prison population
Date of data
Austria 10–20% 2000
Belgium 32–42% 1.12.93
Denmark 19–36% 1999
Finland 15.2–31% 1.5.1999
France 32% 1997
Germany 20–30% 31.3.1999
Greece 26–33% 1995
Ireland 30–52% 1998
Italy 25–29% (15 097) 31.12.99
Luxembourg 36% 1.6.1999
Netherlands 14–44% 1997/8
Portugal 37.7–70% 31.12.98
Spain 35 –54% *
Sweden 47% 1.10.1999
England/Wales 15–29% *
                                                
2 Except Belgium where more wom en are incarcerated for drug offences, but less drug use in female
prison sections occurs .
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Scotland 18–33% 1998
* not available
II.3. Specific groups – migrants, women and young offenders
The proportion of prisoners with foreign nationality or of other ethnic origin (as far as
figures are available) is very high in all countries (average 18–20%) except for
Ireland, and is above the average of the migrant proportion in the general population.
“This high proportion of migrants in prisons shows clearly the need for improvement
of group specific research and information for ethnic minorities and foreigners”
(Rotily/Weilandt 1999).
Criminality seems to be to a wide extent a male problem – women on average
representing approximately 5% of inmates in European prisons. This ranges from
1.8% of the total prison population in Greece, to 3% in the Netherlands, 5% in
Germany, 5.7% in Sweden and 9.2% in Spain. Some countries indicate that the
number of imprisoned women has risen considerably over the past decade. In Spain
between 1987 and 1999 the number doubled. In England and Wales this rise
happened in just over a six-year period. The English Home Office report ‘Women and
the criminal justice system’ in 2000 states that women tend to have shorter criminal
histories than men and ‘grow out’ of crime earlier, but are more likely to be arrested
for less serious offences. The reasons for incarceration are generally shoplifting and
other forms of minor theft. The report also reveals that 55% of imprisoned women
have children under the age of 16 and more than a third have a child under the age
of five. The percentage of drug users among women prisoners is very high in most
EU countries.
In some countries, data suggests that two thirds of women entering prison report a
history of severe drug and/or alcohol use prior to imprisonment. Poly-drug use is a
widespread pattern. Between one half and three quarters of drug-using women earn
money for drugs through prostitution (compared with 10% of men).
Female inmates often have more health problems than male inmates. Many suffer
from chronic health conditions resulting from poverty, drug use, family violence,
sexual assault, adolescent pregnancy, malnutrition and poor preventative health
care. Many HIV-positive women do not receive the diagnostic and treatment services
that could benefit them as early as do HIV-positive men. Also, the needs of HIV-
positive women differ from those of men, and social and community support are often
less frequently available and less accessible.
HIV prevalence among female prostitutes was two or three times higher than for
women outside prostitution. It seems that prostitution is a behavioural marker for a
high co-morbidity with sexually transmitted diseases and hepatitis infections, a high
level of everyday stress, and a higher level of drug use. Women also seem to start
taking drugs earlier.
The misuse of prescribed drugs is a major health threat. It is said that in some
countries (England and Wales, France, Germany) there is a widespread use of
psychoactive medication – in particular by women – prescribed by prison doctors.
Drug-using patterns by young offenders may be different from adult ones both in the
community and in prison. An epidemiological study carried out on young offenders
11
found extremely high risk patterns and sero-conversions (HIV, Hepatitis B and C) and
many prison experts confirm this pattern. They report less cautious attitudes to drug
use and higher risks in injecting drug use. This may be due to feelings of inviolability.
This behaviour becomes extremely important in the prophylaxis of blood-borne
viruses.
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III. ORGANISATION AND PRACTICE OF HEALTH CARE AND
ASISTANCE PROVIDED TO DRUG USERS IN PRISONS
KEY FACTS
In all but three of the countries examined (France, Italy, and partly in England and
Wales) health care matters are the responsibility of the Ministry of Justice.
Sometimes there are drug strategy units which develop specific drug strategies for
the whole or part of the country (for example the ‘Prison service drug strategy’ for
England and Wales), or sometimes only for certain regions. In some countries (such
as Denmark) specific steering groups have been set up to observe and monitor
developments and attempt to improve health care for prisoners, especially for drug
using inmates3.
A number of studies have identified disparities between services inside and outside
for drug and alcohol treatment. A variety of international recommendations exist
which use the principle of equity as a basic supposition for the treatment and care of
drug using prisoners. This principle means that prisoners should have access to the
same medical and health care services as they would have outside and that the
external professional standards of care and cure should be applied in prisons.
Medical services are available in all European prisons in one form or another. Larger
penal institutions mostly have their own medical units, while smaller units work
closely together with doctors from the community.
III.1. Models characterised by being under the responsibility of the
Ministry of Justice
Prison hospitals and prison-based psychiatric hospitals for ‘mentally disturbed
criminals’ in certain regions are models for the majority of countries in which medical
care is the responsibility of the Ministry of Justice.
In most European countries treatment plans are provided for every prisoner for the
duration of their prison sentence. This is also the case for former drug-using
prisoners. Most countries use a model of mixed professionals for the care of drug
users: external experts are integrated for consulting and therapeutic purposes and
assist internal professionals in charge of care issues. This type of organisational
structure enhances the link between prisons and the community and ensures the
                                                
3 e.g. Denmark the Directorate of Prisons and Probation has appointed a permanent working group
whose task it is to keep up with development in the area of alcohol and drugs to consider the
principles and possibilities of treatment in relation to users in the institution system of the Directorate.
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continuity of treatment for both drug users entering prison and convicts leaving
prison.
III.2. Models characterised by being under the responsibility of the
Ministry of Health
France, Italy and England and Wales are described below because they have
reorganised their health care services in prison and form an exception4 to the above
general rule.
France. As a result of by-law no. 94-43 dating from 1994 responsibility has been
transferred from the French Ministry of Justice to the Ministry of Health. Each penal
institution cooperates closely with a general or psychiatric hospital team nearby.
These hospital teams provide medical and psychiatric care in the prison. It is the
responsibility of the psychiatrist in charge to provide drug counselling and treatment
services. In 16 large, short-stay prisons there are specialised treatment centres for
drug addicts which are aimed at preparing prisoners for release and coordinating
help facilities in the region. In a few recently built prisons, health care for prisoners is
sub-contracted to the private sector. In the other 170 prisons, external specialist
treatment centres are responsible for drug services which supplement the care of the
medical teams inside and are responsible for preparing drug dependent prisoners for
release. Privately managed correctional establishments are themselves responsible
for providing medical services in accordance with the principles and guidelines laid
down by the health authorities.
Italy. A new law5 has radically changed the position on assistance to drug users in
prisons in Italy. From 1.1.2000 assistance given to drug users is the responsibility of
the local Addiction Treatment Units (SERTs6) which are part of the National Health
Service. This ‘decreto legislativo’ changed completely the way that assistance to drug
users is given in prison, as it is no longer the responsibility of the prisons system.
England and Wales. Rapid development of drug services in prisons is currently
going on. Besides the promotion of 35 detoxification programmes, the increase in the
number of rehabilitation programmes from 16 to 42 and the increase in the number of
therapeutic communities from 4 to 6, CARATS (counselling, assessment, referral,
advice and throughcare service) was introduced in October 1999. This is to be an
integrated, overall strategy focusing on the needs of the great majority of prisoners.
This strategy comprehensively links different services, which in some other European
countries are separate: prisons, community services and probation. CARATS must
be available in every penal establishment via local, cluster or area contacts with
community agencies working in conjunction with prison and probation staff.
Although CARATS and the drug strategy is still in the hands of the Prison Services,
the rest of the healthcare system is now under the responsibility of the Department of
Health into which the Prison Service Directorate of Healthcare has been moved.
                                                
4 A shift from responsibilities for health care from the Ministry of Justice to Ministry of Health is called
for by several experts (e.g. for Ireland: Dr. Joe Barry 2000 in Irish Times 9 Nov. 2000).
5 This is a temporary law that needs to be converted into effective law by Parliament. Parliament could
refuse this; however, in the meantime, it is enforced.
6 SERTs normally operate in the community and some of them in prisons as well.
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III.3. The principle of 'equity' in international guidelines and
recommendations
Although the United Nations has stated that persons ‘deprived of liberty’ retain all
other rights, and most countries are signatories to this convention7, the realities of
prison life – and death – are grim. Disease transmission in prison and the impact on
the general community provides ample reason to consider the public health
implications of incarceration. A number of studies have identified disparities between
services inside and outside of prison, in the fields of diabetes 8, mental health9 and
drug and alcohol treatment. A variety of international recommendations exist which
use the principle of equity as a basic supposition for the treatment and care of drug-
using prisoners. This principle means that prisoners should have access to the same
medical and healthcare services as they would have outside and that the external
professional standards of care and cure should be applied in prisons.
In some countries the principle of equity of care and provision for the continuity of
care is explicitly formulated in official government papers (for example in Ireland). In
practice, however, healthcare provision equivalent to that available in the community
is hardly ever achieved – at least for drug-using inmates. A European study on the
‘Implementation of international guidelines on HIV/AIDS in prisons of the European
Union’ found that the WHO guidelines on ‘HIV/AIDS in prisons’ (1993) are not being
uniformly applied in EU prisons. “In general, the principle of equity between HIV
services in prison and in the community is not applied. In particular, many of the
WHO recommendations on HIV/AIDS in prisons are not implemented”,
(O’Brien/Stevens, 1997). One reason for this is that different government
departments are responsible for the care of drug users in the community than for the
care of drug users in prison. This situation creates inherent problems for the
continuity of care of drug users.
III.4. General health services and examination
Medical services are available in all European prisons in one form or another. Larger
penal institutions mostly offer their own medical units, while smaller units work
closely together with doctors from the community.
In nearly all European prisons every inmate is seen by the prison doctor within the
first 24 hours of admission for a medical check. Nearly all prisons have a health unit
including doctors, nurses and psychologists. Smaller prisons often rely on private
contract doctors. The size of the team varies according to the prison and its
capacities.
                                                
7 Standard minimum rules for the treatment of prisoners:
http://www.unhchr.ch/html/menu3/b/h_comp34.htm
8 MacFarlane, I. A., ‘The development of health-care services for diabetic prisoners ’. Postgrad Med J
1996; 72: 214-217.
9 Hargreaves, D., ‘The transfer of severely mentally ill prisoners from HMP Wakefield: a descriptive
study’. J Foren Psych 1997; 8: 62-73.
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Patients with special health needs are mostly referred to the prison hospital. They
may also be referred to other facilities in the prison system or to general health
services.
In all EU countries, HIV tests are generally available for prisoners, mainly on
admission. In some countries, tests are offered systematically to all prisoners
entering prison. In practice though there are differences in how proactively this is
done.
In most countries, prisoners are tested according to a clear protocol10 with an
informed consent procedure. The HIV test results are normally not communicated to
the prison administration, are strictly confidential and kept in the health record.
However, in some prisons, HIV positive results are communicated to prison directors.
A study carried out in 1997 found that in a third of 23 examined prison systems the
identity of seropositive prisoners is routinely communicated to the prison
administration. In seven other systems, the identity of seropositive prisoners is
communicated ‘when necessary’ to the prison administration.
In a few countries, positive HIV tests have certain consequences for prisoners. In
some states of Germany, and also in Greece, HIV-infected prisoners may be placed
in single cells, and if they want to share a cell with other persons other inmates are
informed about their serostatus. In some countries, HIV-positive (as well as hepatitis
B and C positive) inmates are excluded from kitchen and/or barber work. Here again,
the situation is difficult to evaluate because within each prison system the directors
have a discretionary power which allows them to freely organise the placing of
prisoners.
                                                
10 For instance, in the Netherlands ‘Protocol HIV-Testbeleid in Justitele Inrichtingen’ from July 1994.
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IV. INTERVENTIONS WITH A FOCUS ON DEMAND
REDUCTION
KEY FACTS
Drug services in EU prisons have undergone considerable development recently.
There is an appreciable and increasing range of interventions focusing on drug users
in prison. A study of 15 European Union Member States concludes that all of them
provide some form of treatment activity in their prison system11. Despite that, there
appear to be large gaps in the adequate provision of treatment, care and prevention
in prison systems. WHO/UNAIDS (1997) confirm this in a study of 23 prison systems
in 20 European countries, representing 387 000 prisoners.
IV.1. Abstinence-oriented treatment
Abstinence-oriented treatment for prisoners is provided predominantly in
special facilities (drug-free wings, therapeutic communities) – and is the
dominant approach in existing interventions. Some countries have shown an
increase in drug-free areas since the mid-nineties of three- to fourfold (Austria,
England and Scotland). Access to these programmes is voluntary under
certain conditions and sometimes even with certain contracts for behavioural
change. The central objective is abstinence, and therefore urine testing plays
a major role in ensuring drug-free status. These programmes are mostly run in
separate sections of the prison with no direct contact with other inmates and a
high level of control. The ‘twelve steps’ concept is the most common. Drug-
free wings have been developed particularly in Austrian, Dutch, Finnish and
Swedish prisons.
A 1998 study found that 80% of all Council of Europe countries have
abstinence-based programmes. In most countries a differentiated system of
sanctions and incentives has been developed in prisons in order to punish
                                                
11 Turnbull/Webster 1998.
12 Bollini 1997 suggests installing demonstration projects to implement the WHO guidelines on
HIV/AIDS in prison as an example: These pilot projects should be supervised and co-ordinated by
UNAIDS or WHO: “The presence of international organisations would provide symbolic and scientific
authority to the program, and would ensure effective dissemination of its results. It is important to
stress that harm reduction projects in the participating countries should not necessarily be the same,
but should respond to the current needs of each partner. Each project should implement, and duly
evaluate, one aspect of WHO Guidelines....”.
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drug use or to reward drug abstinence within a unit or treatment programme.
These measures are designed as deterrents for prisoners within the
framework in which treatment efforts are organised. Sanctions might be:
additional days of imprisonment for positive urine tests, forfeitures of
privileges, stoppage of earnings, no home leaves, or no visits. Incentives are
designed to encourage good behaviour of prisoners.  These may be a transfer
to a drug-free wing, single cell, home leave, holiday, in-cell television etc.
IV.2. Substitution treatment
Substitution treatment has been widely introduced in prisons only during the
nineties. Provision of methadone treatment within prisons varies considerably
between countries. Spain and Austria have high levels of provision. In Spain,
it is estimated that 60% of drug users in prison receive methadone. In Austria,
maintenance treatment has been offered in all prisons since 1991, and social
and psychotherapeutic approaches are also offered. Prisons in Portugal
provide methadone for maintenance purposes but in Belgium, Germany,
Ireland, Italy, the Netherlands and the UK, provision is minimal, apart from for
the purposes of detoxification. Sweden and Greece do not provide methadone
in prisons. Eligibility for entering a methadone programme in prison largely
depends on levels of treatment provision. In all countries where a programme
is available, a user receiving treatment outside prison can continue treatment
inside. In the UK, where provision is low, it is estimated that a third of those
who are receiving methadone treatment before entering prison also receive it
in prison. In Austria, Portugal, Spain and parts of Germany, however, a drug
user can begin treatment on entering prison.
Austria. Since 1991, all prisons in Austria have been offering maintenance
therapy with substitution substances during a prison sentence. Some prisons
offer specific units for substitution. The prison in Favoriten (Vienna)
specialises in the treatment of addicts. Amongst other things prisoners might
be offered substitution treatment but they can also acquire psychotherapeutic
and social support, such as job training in the form of an apprenticeship.
These approaches are offered in addition to medical treatment.
Belgium. Since 1995 methadone has been used in some prisons. Methadone
substitution treatment can be continued in prison, but at present this is only for
patients who were in substitution treatment before being incarcerated. At
present, treatment in prison consists of progressive withdrawal, but it is
anticipated that substitution treatment will be initiated in prison for
maintenance for specific groups.
Denmark. The policy of the Direktoratet for Kriminalforsorgen (Directorate for
Prison and Probation Services) is that drug users in prison should be offered
treatment coordinated with the social services and treatment institutions
outside prison. In principle, treatment (including substitution treatment) should
not be interrupted because of imprisonment.
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Finland. Continuity of care has not been a problem during the three and a half
years of a pilot programme. Four patients of the substitution treatment clinic
continued receiving methadone substitution while in prison in 1998.
France. According to the results of a 1998 survey carried out by the Ministry
of Health, substitution treatment discontinuation is a major problem: 22% of
new inmates taking buprenorphine and 13% of those taking methadone
ceased within eight weeks of incarceration. The principle of continuation of
treatment in prison confirms that substitution treatments may be continued or
started in prison with methadone or SubutexÒ. The medicine must be
dispensed by the medical staff. To facilitate the integration of the correctional
health service into the care system, a doctor practising in prison must be
included in the departmental monitoring committee. The doctors of the
prisons’ internal medical services are invited to contact the attending
physician and to organise continuation of treatment after release. There is a
continuation of treatment on release: 95% of former prisoners taking
methadone and 79% of those taking SubutexÒ  receive medical support on
leaving prison.
Germany. Currently, no exact figure for methadone patients in penal
institutions is available  but it is estimated at around 800. Only six of the 16
federal states provide methadone treatment in prisons (Berlin, Bremen,
Hamburg, Hesse, Lower Saxony and North Rhine Westphalia) predominantly
for detoxification purposes. Prescription or methadone maintenance is poorly
developed. Entry criteria as well as detoxification procedures vary
considerably between states, and substitution treatment is not available in all
of the prisons of these states.
Ireland. In theory, prison policy is to provide the same level of substitution
treatment inside prison as outside, but in practice this does not happen. There
is one detoxification unit and one small maintenance clinic in the largest
prison (with approximately 20 prisoners on this programme at any one time).
“There is a standard detoxification programme of 14 days, which is offered to
prisoners on committal if they are found to test positive for opiates. Prisoners
that may have been stable on methadone in the community are generally
detoxified upon incarceration” (Dillon, 2000). The situation has changed
considerably in the Irish Prisons Service. Methadone maintenance was
introduced in early 2000 to the new remand prison at Cloverhill (capacity up to
400 places) for prisoners who were on maintenance programmes in the
community. This development was extended to the largest prison in the state,
Mountjoy Prison (capacity 670) at the end of 2000. For those not receiving
treatment before arrival in prison, in certain circumstances (for example HIV-
positive status) substitution treatment can be commenced in prison.
Italy. Substitution treatment is received by 500 drug users out of the total
14 000 in prison (as of December 1997). Lack of continuity of treatment
between the healthcare system and prison is also a major problem.
Luxembourg. Clients who are in methadone treatment before their detention
continue their treatment during remand and, in cases of a long prison
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sentence, undergo slow detoxification. A prisoner is allowed methadone
before his release.
The Netherlands. Almost all IAVs (the 16 Instellingen voor Ambulante
Verslavingszorg or Institutions for Ambulatory Addiction Treatment and Care)
offer a maintenance and reduction programme. Over two  thirds of clients
attend maintenance programmes in the communities. One exception relates
to programmes in detention centres, where addicted prisoners who are to
spend more than a few weeks in detention are obliged to follow a reduction
programme.
Portugal. Where methadone units are available, prisoners sign a treatment
contract.  In prisons with no methadone unit prisoners are supervised by the
nearest Ministry of Health (CAT) treatment centre. Agreement is reached
between the two services as to the use of either methadone or LAAM.
Spain. A 1990 law included a paragraph on methadone use in prisons.  In
August 1997 all prisons (except two) had already developed methadone
maintenance programmes. These were not abstinence-oriented. When
subjects are discharged from prison, they are referred by the prison to
continue methadone maintenance in an outpatient centre.
Sweden. Methadone maintenance treatment is not available in Swedish
prisons since one of the inclusion criteria for maintenance treatment is that the
patient shall not be in custody, under arrest or in prison at the time of
admission.
England/Wales. There has been considerable expansion in the growth of
methadone detoxification for prisoners, but only a very limited amount of
methadone maintenance.
Prescribing substitutes is one of the most common forms of treatment
delivered by community treatment agencies. There is a very low level of
continuity between community methadone treatment and prison methadone
treatment. For those sentenced, there are reasonable levels of contact with
outside specialist agencies. Short-term methadone detoxification is the most
widespread approach for drug users. For example, in the women’s and
juvenile prison HMP Holloway in London, 1 500 withdrawal treatments are
carried out annually.
Scotland. Methadone maintenance programmes reflect the prisoner’s specific
conditions (clinical profile, judicial and penal situation). Contact with the
community prescriber is then made to confirm dosage, compliance and
willingness to continue prescription on release. If a prisoner on a community
methadone programme is to be in prison for more than three months, a
reduction programme may be prescribed if certain conditions are met.
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Table 4: Availability of substitution treatment in EU prisons
MaintenanceCountry Detoxification
short-term
prisoner
long-term prisoner
Substitution
substance
predominantly
used
Austria Methadone
Belgium Methadone
Denmark Methadone
Finland Methadone,
Buprenorphine
France Methadone,
SubutexÒ
(Buprenorphine)
Germany Methadone
Greece
Ireland Methadone
Italy Methadone
Luxembourg Methadone
The
Netherlands Methadone
Portugal Methadone, LAAM
Spain
Sweden
England and
Wales
Methadone mostly;
Lofexidine in some;
Dihydrocodeine
Northern
Ireland
Scotland
Few
prisons:
Most
prisons:
All
prisons:
No prisons:
IV.3. Detoxification
Detoxification facilities (although varying in length and form) are offered in
nearly all Member States. Detoxification policies vary from country to country
and from region to region especially in those with a federal structure.
Methadone treatments are only implemented properly in a small number of
prisons in order to reduce the  physical and psychological withdrawal
symptoms. A specialist withdrawal treatment based on medication also
permits the detection and handling of side effects and potential sources of
infection.
Contrary to new detoxification therapeutic standards, addicts in many
European prisons are still subject to ‘cold turkey’ (immediate reduction of the
dosage to zero) upon incarceration. Sometimes prisoners have to cope with
the symptoms of withdrawal on their own (not least in order to punish them) or
they are not treated on time or occasionally not at all. There are also cases in
which staff at the healthcare units give tranquillisers to inmates which do not
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have any effect on most of the withdrawal symptoms. While withdrawal from
methadone outside prison takes place gradually, the dosage given inside
prison is often reduced rapidly.
Germany. In many clinics, withdrawal of opiates (or partial withdrawal in
cases of multiple addiction) is increasingly treated with medication. ‘Cold
turkey’ has been replaced with a more pragmatic approach: addicts are
treated with medication which permits an intense analysis of the psychosocial
causes and circumstances of addiction.
Ireland. Two forms of detoxification are offered: an intense 14-day
detoxification programme, or a detoxification programme which lasts thirteen
weeks and involves a support group and counselling. After this programme,
prisoners are either transferred to the training unit (a drug-free semi-open
institution) or granted temporary release.
England. ‘Post Detox Centres’ have been created, such as the one in
Holloway Prison. This is a community in which residents and staff work
together to create a supportive and confidential environment where inmates
can explore drug- and alcohol-related problems during their time of
incarceration. The aim is to help inmates become drug free and cope with
staying drug free, both in prison and on their release. The inmates may stay at
the centre for up to three weeks.
IV.4. Drug-free units and drug-free wings
Drug-free units were developed at the beginning of the nineties, but did not
reach some countries until the late nineties. In several countries the number of
places is rapidly increasing (e.g. Austria). Despite this development there is
very little scientific evaluation work that has been carried out.
The focus in these units is on drug-free living mostly combined with
community living, in order to utilise a positive group atmosphere and the
effects of peer group education in treating addiction. The basic characteristics
of drug-free units are: (a) the prisoner stays in these units on a voluntary basis
(b) he/she is committed (sometimes with a contract) to abstinence from drugs
and not to bring in any drugs, and (c) he/she agrees to regular medical check-
ups often involving drug testing. The prisons system is committed to prisoners
staying in these units to enjoy a regime with more favours, such as additional
leave, education or work outside, excursions, more frequent contact with the
family etc.
As distinct from ‘drug-free units’, the term ‘drug-free wings’ usually does not
include an addiction treatment offer. The sole aim of these wings is to offer a
drug-free environment for all those who wish to stay at a distance from drug-
using inmates. The essential difference between ‘drug-free units’ and ‘drug-
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free wings’ is that prisoners entering the latter are not necessarily addicted to
drugs.
In Portugal, drug-free units account for almost half of all general health
facilities provided to prisoners (304 beds out of 741). These drug-free units
include a variety of treatment offers such as ‘therapeutic communities’ units,
methadone maintenance, motivation to treatment, and ‘drop in and drop out’.
Moreover, in other prisons (juvenile and women prisons) healthcare facilities
for drug-using inmates are provided. The primary policy is to provide drug
addicts with similar conditions as those outside prison. In France, a pilot
project started in 1998 where inmates voluntarily work on their addiction
problems (with alcohol, pills and illegal drugs) for 3 months. In Denmark,
contract treatment is distinguished from drug-free units.
Table 5: Places in drug-free units in some Member States
Country Places Source
Austria 700 *
Belgium 16 (a specific programme in one prison in the
Flemish region)
De Maere, 2001
Denmark 1 unit in a closed state prison (16 male)
1 unit in an open state prison (22 male/female)
Reventlow, 2000
France No drug-free units Khodja, 2001
Ireland 170 (1 semi-open institution training unit 96
places), 1 drug-free wing in a juvenile closed
institution (St. Patrick’s – 74 places)
*
The Netherlands 476 (3.6% of total cell capacity) Van Alem et al.,
1999
Portugal 304 beds (from a total of 741 beds in the health
units of the whole system)
Machado
Rodrigues, 2000
Spain In 1999, 6 456 inmates were included in drug-
free programmes in 14 prisons (including
therapeutic drug-free orientated measures and
day clinic);
1 299 inmates received naltrexone antagonist as
support
Ballesteros, 2000
Sweden 346 Krantz/Ekström,
2000
* Not available.
IV.5. Self-help groups
In some countries, self-help groups appear to constitute the main approach in
the support of incarcerated drug users and their families. In Greece for
instance, they are run on a voluntary basis by NGO institutions . In Spain, in
79% of penitentiary centres community personnel have participated in the
development of intervention programmes for drug dependence. The majority
of these belong to non governmental organisations and include staff who are
ex-addicts and ex-convicts.
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IV.6. Auricular acupuncture
In several prisons in Europe, auricular acupuncture is used as a low-cost and
popular method of assisting prisoners to detoxify from drug dependence or to
remain abstinent. Helpful to prisoners in several ways, auricular acupuncture
is used in some prisons in England/Wales (e.g. HMP Holloway), Finland and
Germany (the state of Hamburg).
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V. INTERVENTIONS WITH A FOCUS ON HARM REDUCTION
KEY FACTS
Harm-reduction measures have been developed in the past 15 years
throughout Europe as a supplementary strategy to the existing drug-free
oriented programmes. These measures are integrated differently into the
prison environment. In fact, only a limited number of prisons have been
discussing drug use in their institutions and have adopted harm-reduction
measures which have proved successful outside. The main argument against
the integration of harm-reduction measures in prisons is that it conveys the
‘wrong message’ and makes illicit drugs more socially acceptable.
In most European prison systems information for prisoners and staff is
provided: condoms are distributed in 18 of the 23 systems; disinfectants are
available in 11 systems.
V.1. Vaccination programmes
Vaccination against hepatitis and tuberculosis takes place in many prisons to
avoid infectious diseases or re-infection.
Whether a proactive approach to offering the vaccination is adopted or
whether it is a medical service ‘on demand’ makes a big difference. In France,
a study reported that although hepatitis B vaccination is available in all
prisons, not many prisoners know this or ask for it.
V.2. Provision of disinfectants
This practice of providing disinfectants is not widespread. According to the
World Health Organisation’s information on HIV/AIDS in prison, 16 of the 52
prison systems surveyed have made bleach available to prisoners from 1991.
Only in a few countries do national recommendations exist regarding the
provision and use of disinfectants. In most EU Member States, bleach is either
not available or is provided for cleaning purposes and not distributed officially.
Bleach is available – even if not officially for the sterilisation of injecting
equipment – in Germany, France, Spain, Switzerland, Belgium, Luxembourg,
and the Netherlands. Often information on how to use bleach to sterilise
syringes properly is also provided.
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Austria. In 1994, the Ministry of Justice recommended practically proven
measures to prevent the transmission of infectious diseases to all prisons.
Denmark. Between 1996 and May 2000 prisoners could obtain large bottles
of bleach in the toilets. Prisoners used it for purposes other than disinfection
and therefore the policy changed so that only small bottles could be obtained
– either in the medical department or in the toilets.
Scotland. Bleach/sterilising tablets have been distributed in all Scottish
prisons since 1993 together with an information leaflet giving practical
instructions on how to use it to sterilise mugs, cutlery, razors, chamber pots
and injecting equipment.
Spain. Every prisoner is given a kit with different toiletry products. This
includes a bottle with bleach. All drug users receive instruction and leaflets
about the cleaning of injecting equipment. Every three months they are given
another bottle, but it is also possible at other times to buy it cheaply in the
prison shop.
Table 6: Provision of bleach in some Member States
Country Distribution of
bleach
Substance, kits used Remarks
Austria Betaisodonna
(Jodum)
Medical department. In 26 out of 29.
Belgium
Denmark Natriumhypochlorit Direct access preferably in bathrooms or toilets.
Medical departments only if distribution in bathrooms
etc. is not possible because of sabotage.
Finland Potassiumper-
Sulphate
Individual kit given to every incoming prisoner, freely
available in washing rooms and from health care unit.
France 1 small bottle of 120ml
for every prisoner
every 15 days.
By penitentiary administration (D. Khodja 2001).
Germany
Greece
Ireland
Italy
Luxembourg Not available (Reuland/Schlink 2000).
The
Netherlands
Bleach should be available in every prison.
Portugal In 39 out of 53 prisons. Bleach is distributed when
prisoner enters prison, continues to be regularly
distributed according to the criteria of each prison.
UK
Spain Bottle with bleach. Prison shop.
Sw eden
Few prisons: Most
prisons:
All prisons: No prisons:
V.3. Needle exchange programmes
Needle exchange programmes are generally an efficient and well-
implemented component in prevention strategy outside prison in Member
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States.  However, they are not implemented inside prisons in most EU
countries (except Germany and Spain). Some countries do not have an official
policy against needle-exchange facilities, whilst others explicitly reject this
option.
Similarly, innovative pilot projects under which clean drug injection equipment
is made available in prisons have been launched as a trial in Switzerland,
Germany and Spain. Currently this measure is carried out in 19 prisons (see
Table 7).
Table 7: Needle Exchange Programmes (NEP) in EU and Swiss prisons
(chronologically)
Prison Site Size Character Sentenced NEP since
/evaluated?
Provision
of sterile
syr inges
Exclus-
ion
Prevent-
ive
measures
Men’s prison
Oberschöngr
ün
Solothurn,
Switzerland
75 Half-open Adults 1992 Doctor/
medical
depart.
Non-DU · 
Women’s
prison
Hindelbank
Bern,
Switzerland
110 Closed Adults 1994/yes Slot
machines
(1:1
exchange)
No · 
Men &
women’s
prison
Champ
Dollon
Geneva,
Switzerland
No
detail
Remand
prison
Adults 1996 Doctor No · 
Women’s
prison
Vechta
Vechta,
Germany
169 Closed &
remand
dep.
Adults/
juveniles
1996/yes Slot
machines
(1:1
exchange)
Women
in
Metha-
done
prog-
ramme,
receptio
n dep.,
Non-DU
· 
Men’s prison
Lingen I Abt.
Groß
Hesepe
Groß
Hesepe,
Germany
228 Closed Adults 1996/yes Hand-to-
hand
drug
counsel-
ling
service
Men in
Methad
one
prog-
ramme,
Non-DU
· 
Men’s prison
Vierlande
(with a
section for
21 women)
Hamburg,
Germany
319 Open Adults 1996/yes Slot
machines
(1:1
exchange)
+ hand-to-
hand)****
No · 
Men’s prison
Centro
Penitenciario
de Basauri
Vizcaya,
Spain
250 Half-open Adults 1997/yes Hand-to-
hand
· 
Men’s prison
Realta/Cazis
Graubünden,
Switzerland
100 Half-open Adults 1997/yes Slot
machines
(1:1
exchange)
No · 
Women’s
prison
Lichtenberg
Berlin
Berlin,
Germany
Ca.
40-
50
Closed Adults/
juveniles
1998/yes Slot
machines
(1:1
exchange)
****
No · 
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V.4. Provision of condoms
Nine of the fifteen EU countries have clear official policies allowing free
access to condoms for prisoners, in line with WHO guidelines. The other six
occupied different positions from the extreme of prohibition (based on lack of
recognition of the problem) towards allowing access.
Table 8: Provision of condoms
Country Provision of
condoms
Remarks
Austria Available in 20 out of 29, in 3 only on 'demand', in 4 not at all, in one 'in
preparation'
Belgium Varies widely depending on local prison policy
Denmark Freely available in all prisons since 1987. Can be obtained from the prison staff
and medical service. Placed in visiting rooms
Finland At intake (entering and leaving), by medical unit, in conjugal rooms, freely
available without asking
France Medical service
Germany Medical service, merchandiser, social worker/ psychologists.
In some prisons it is difficult to purchase a condom when needed: it has to be
ordered 7-14 days in advance
Luxembourg Condoms and lubricants available in the medical department, prisoners do not
have to ask for them, they can just take them out of a container
The
Netherlands
Guidelines stated that condoms must be available in every prison. It is up to
every local governor to make his own policy on the practical form of availability.
Portugal
40 out of 53
Medical office, nursery, educational body
According to the criteria of the prison administrators
Spain At entry, after that in all cells where prisoners meet visitors, also on demand at
medical service
Sweden Available in cells where prisoners meet visitors
Few
prisons:
Most
prisons:
All
prisons:
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VI. INTERVENTION WITH A FOCUS ON COMMUNITY LINKS
KEY FACTS
Specific legislation in a number of countries has attempted to enhance links
between the criminal-justice and health services in order to reduce the
number of drug users entering prison. Despite this development, the size of
the addicted population in prisons has grown. This development emphasises
the need for better links between criminal-justice agencies and drug services.
Alternative measures to prison for drug-addicted inmates (such as residential
treatment outside prison), pre-release and aftercare interventions, as well as
work with families and the maintenance of family and social ties are essential
components of intervention which focus on the preservation of community
links.
The principle of ‘treatment instead of punishment’ is adopted in most
European countries. In fact, the court may suspend the sentence and the
accused can go voluntarily into an in-patient treatment centre or into
ambulatory centres which are slowly but surely accepted as treatment options.
Several studies show that effective aftercare for drug-using prisoners is
essential to maintain gains made in prison-based treatment. Despite this, it is
a  widely acknowledged fact that prisoners often have difficulties in accessing
and paying for treatment on release under community-care arrangements.
Through care has been developed as multi-agency cooperation in some
countries, which involves intensive integration of outside agencies to continue
these efforts at the time of release.
Working with families of prisoners is a central part of rehabilitation and social
reintegration in many countries.
VI.1. Pre-release units and release
Most of the countries examined make strenuous efforts to reduce relapse and
to provide social reintegration. Preparation for release is different in the 15 EU
countries. Aside from basic social and health aims, one central aim is to
continue support after release.
Austria. In the prison 'Vienna Favoriten' there is intensive support in the
months preceding release. This is an intensive and additional programme to
normal pre-release measures. Although an evaluation showed that the goal of
continuity of support could only be achieved in 10% of the cases, the subjects
judged the offer as helpful and important to prepare for life outside prison.
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France. In seven prisons pre-release units have been established in order to
offer groups of up to ten drug-using prisoners a voluntary four-week course of
group treatment with the aim of preparing them for release.
Spain. Drug-dependent people who have been under treatment during their
stay in prison are able to continue therapeutic care when they are finally,
conditionally or provisionally freed. During 1998, 7 180 people were
transferred to community programmes (40.7% more than in 1997).
Denmark. A treatment plan should be drawn up for each inmate and co-
ordination should be ensured between the prison and social authorities when
planning release and aftercare. Official guidelines have been drawn up by a
working group with representatives from the Ministry of Social Affairs and the
Department of Prison and Probation.
VI.2. Aftercare
Austria and Sweden have a far more integrated system of aftercare than is
found in most countries. Aftercare in Sweden and Austria is largely built into
the sentence plan.
VI.3. Working with families and maintaining family ties
Working with families of prisoners is a central part of rehabilitation and social
reintegration in many countries. In some countries, special ‘family contact
development officers’ are employed.  These help families to keep or initiate
contact, help to work on relatives’ drug problems, inform families about drug
problems in prison and outside, and help to enhance family visits. In some
countries (such as Denmark and Switzerland) prisoners are given the
opportunity to receive visits from their partners without supervision. Similarly,
in Sweden supervision is fairly relaxed.
VI.4. Counselling at various stages of imprisonment
Counselling is a direct, personalised, and client-centred intervention. It is
designed to help initiate behaviour change to keep off drugs, avoid infection
or, if already infected, to prevent transmission to other inmates or partners. It
is also designed to assist referral to additional medical care and preventative,
psychosocial or other necessary services in order to remain healthy.
VI.5. Through care
In some countries through care is perceived as the crucial factor in the
success of tackling drug use in prison. The English/Welsh ‘Prison service drug
strategy’ gives a definition of the concept – “By through care we mean the
quality of care delivered to the offender from initial reception through to
preparation for release, establishing a smooth transition to community care
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after release”. This definition implies direct links with sentence management
or with incentives and earned privileges schemes. Through care is similarly
defined by the Scottish Prison Service.
VI.6. Treatment for sentenced offenders outside prison
Several countries have legal regulations to suspend the sentence for drug
users, if the alternative serves to assist their subsequent rehabilitation in the
community. In Sweden, the Prison Treatment Act states that a prisoner may
be permitted – while still serving his prison sentence – to be placed in a
treatment facility outside prison.
Alternatives are mostly related to the length of sentence. For example, in
Germany law allows prisoners to undergo ‘treatment instead of punishment’
when the sentence to serve is no longer than 2 years. In Greece, after a
period of seven to ten months in custody, a drug user may apply to the public
prosecutor to continue treatment outside prison. This is the result of a law
specifically designed to allow drug users to receive therapeutic treatment
rather than stay in prison.
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VII. Evaluation of interventions of assistance to drug users
in prisons in the EU
KEY FACTS
Prisons remain an area where there is major variation in levels of provision.
There are limited evaluation data to guide policy-makers in determining the
best course of action for the future. More evaluation of delivered prison
treatment is needed
VII.1.  Evaluation criteria
To obtain reliable and comparable data, evaluation criteria for demand and
harm-reduction interventions have to be developed. Overall issues in the
definition of evaluation criteria are: feasibility, degree of acceptance, and
effectiveness of the measures undertaken, taking into account the different
interests and values of the persons and institutions involved.
As regards interventions, it is of particular importance to determine if changes
in drug use behaviour occur. The following criteria may be used as a basis for
this analysis:
· abstinence from drugs (abstention from drug use during specified periods);
· reduction of drug use (consumption of smaller amounts);
· reduction of harmful and damaging drug use (changes in drug-using
patterns, changes in drugs used, avoidance of overdoses);
· reduction of harmful and damaging drug-use patterns (e.g. shift from
injecting to smoking);
· improvement of risk-related knowledge ('safer-use', 'safer-sex');
· improvement of health status; and
· improvement of social and communicative skills and competence (e.g.
participation in treatments offered, compliance with rules dominating the
treatments, participation in self-help groups, involvement in peer support
activities).
The prison system itself may also be the subject of an evaluation. To study
the effects of interventions, the following criteria can be applied:
· scale of acceptance of the measures by prison officers, medical staff and
management;
· changes in the attitude towards drug-using prisoners;
· level of credibility of the preventive measures;
· impact of the measures taken on security matters;
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· consequences of participation in treatments offered for the length and
quality of the sentence to be served by inmates
(advantages/disadvantages, impact on family visits, home leaves etc.).
VII.2.  Results of evaluations
A literature survey15 (of mostly North-American literature) on the effectiveness
of the criminal-sanction system, including correctional treatment in general
and treatment designed for specific types of offenders (drug addicts amongst
others) found out that programmes based on cognitive-behavioural principles
seem to be the most effective. Some features of programmes most closely
linked with success are:
· a theoretically sound concept;
· programme integrity;
· competent staff, good physical conditions, structured setting;
· thorough assessment of the offender and targeting his specific
criminogenic needs;
· intensive service for high-risk delinquents (those at greater risk of
recidivism);
· relapse-prevention and aftercare.
                                                
15 conducted by the Scientific and Documentation Centre of the Dutch Ministry of Justice (2000).
